Abstract
Osteoarthritis (OA) is a joint disease that causes pain and degeneration in the affected area. There are no standard guidelines for agents that can slow down or modify the disease's progress. Diacerin is one such agent used to improve symptoms of OA. The objective was to analyze its efficacy in different grades of OA. A quasi-experimental study was conducted at Ghurki Trust Teaching Hospital in Lahore over six months from Jan 2023 to July 2023. After obtaining informed consent and meeting inclusion and exclusion criteria, we included 78 patients with grade II and III OA (39 each). All patients were given Diacerin (100mg twice daily). The baseline Western Ontario and McMaster Universities Arthritis Index (WOMAC) and pain on the Visual Analogue Scale (VAS) were used to measure the treatment's efficacy in improving symptoms after six months. The data was analyzed using SPSS 23.0. The mean age of the participants was 53.98+6.17 years. The mean WOMAC score was 49.62+7.81 before treatment, which decreased significantly to 38.34+8.79 after six months of treatment (p-value <0.05). The mean VAS score before and after treatment was 7.41+0.98 and 4.82+1.07, respectively. These findings suggest that Diacerein significantly reduces pain and improves functional ability in patients with OA of the knee joint. This treatment was safe and well-tolerated. Its use is recommended in early grades of OA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
